7月1日 - ** 医疗设备制造商Guardant Health的股价上涨10.6%，至165.96美元
** Evercore ISI认为，UnitedHealthcare扩大对Guardant Health旗下 GH.O 血液结直肠癌筛查检测（Shield）的承保范围，将带来上行空间
** 该券商表示，UnitedHealthcare已更新其《分子肿瘤学检测》医疗政策，将“Shield”纳入保障范围，认定其作为平均风险结直肠癌筛查具有医疗必要性
** 该政策适用于联合健康保险的商业保险计划及个人保险交易所计划，保障自8月1日起生效
** Evercore ISI指出，这一决定意义重大，因为联合健康保险将“Shield”列为一线筛查选项，这意味着患者无需先拒绝或未能完成其他筛查方法即可使用该检测
** 该经纪公司补充称，UnitedHealthcare的此举可能会鼓励其他商业保险公司提供类似的承保
** 截至上一交易日收盘，UNH股票今年以来累计上涨约29%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.